Tranzend, Inc. (C-corp, Cupertino, CA): Early-stage startup developing a blood-screening test for accurate, early detection of breast cancer. In collaboration with Stanford, our unique microRNA “deep-dive” approach, novel lab workflow, and algorithms will enable fewer missed cancers and reduce unnecessary biopsies.
Business Model: Limited reimbursement with initial CLIA LDT launch; broader reimbursement enabled by a final IVD launch.